Algorae Pharmaceuticals (ASX:1AI) is working with the Victorian Center for Functional Genomics (VCFG) at Peter MacCallum Cancer Center to validate artificial intelligence-predicted drug interactions through screening, according to a Thursday filing with the Australian bourse.
The study will assess 24 drug candidates using VCFG's advanced screening platform to confirm drug combinations' efficacy across four cancer cell lines, the filing said.
The data analysis is expected to be completed within three weeks of each screen run, with the full dataset expected to be completed within six months, per the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。